Metastatic Tumor Clinical Trials

7 recruitingLast updated: June 17, 2026

There are 7 actively recruiting metastatic tumor clinical trials across 5 countries. Studies span Phase 1, Phase 2, Phase 3. Top locations include Augusta, Georgia, United States, Austin, Texas, United States, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


Metastatic Tumor Trials at a Glance

7 actively recruiting trials for metastatic tumor are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in Augusta, Austin, and Beijing. Lead sponsors running metastatic tumor studies include Mohammed Milhem, Neowise Biotechnology, and David Palma.

Browse metastatic tumor trials by phase

Treatments under study

About Metastatic Tumor Clinical Trials

Looking for clinical trials for Metastatic Tumor? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

Metastatic TumorSolid TumorLocally Advanced Solid Tumor
Mohammed Milhem35 enrolled1 locationNCT07404332
Recruiting
Phase 1

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Triple-Negative Breast CancerGastric CancerOvarian Cancer+25 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 3

A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.

Metastatic Tumor
David Palma180 enrolled5 locationsNCT05717166
Recruiting
Phase 1

TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors

Solid Metastatic Tumor
Neowise Biotechnology24 enrolled1 locationNCT07266298
Recruiting
Phase 1

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Ovarian CancerAdvanced Solid TumorMetastatic Tumor+2 more
Weijia Fang, MD30 enrolled1 locationNCT05518253
Recruiting
Phase 2

Definitive Radiation for High-Risk Spine Metastases

Metastatic Breast CancerMetastatic CancerMetastatic Lung Cancer+5 more
Stony Brook University26 enrolled1 locationNCT06165419
Recruiting

Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients

Prostate CancerMetastatic TumorHormone Sensitive Prostate Cancer
Santa Chiara Hospital3,000 enrolled3 locationsNCT06473259